CDEK
← All drugs Report issue

nepadutant

Small moleculeexperimental

Nepadutant (INN; development code MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK2 receptor antagonist. It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed. — Wikipedia

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2008 (NCT00655083)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CNC(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2
Mol. weight
947.02 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cyclo(asn(2-deoxy-2-acnh-beta-d-glc)-asp-trp-phe-dap-leu)cyclo(2beta,5beta)
  • men 11420
  • men-11,420
  • nepadutant
  • nepadutant
  • nepadutant
  • nepadutant
  • nepadutant

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01532518Phase 2Aug 1, 2011Menarini Group, University of Toledo
NCT01309009Phase 2Feb 1, 2011Menarini Group, University of Florence
NCT01258153Phase 2Nov 1, 2010Menarini Group
NCT00655083Phase 1Mar 1, 2008Case Western Reserve University, Menarini Group
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Menarini GroupFor profit4422008
Case Western Reserve UniversityAcademic/Hospital1012008
University of FlorenceAcademic/Hospital1012011
University of ToledoAcademic/Hospital1012011
4 organizations
Page 1 / 1